Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)

Uppsala University

Status: Completed

Conditions: Spinal Fractures; Ankylosing Spondylitis

Treatments: Drug: bDMARD treatment

Study type: Observational

Funder types: Other

Identifiers

NCT02840695

bDMARD AS Spinal Fractures

Details and patient eligibility

About

Ankylosing spondylitis (AS) is a rheumatoid disease affecting all segments of the axial skeleton, leading to the complete fusion of all spinal segments - the bamboo-spine. During the last decade biological disease modifying anti-rheumatic drugs (bDMARD) have been successfully introduced to reduce the disease activity. It is unclear whether bDMARD treatment had an effect on spinal fracture risk related to AS. This national registry study will investigate the effect of bDMARD treatment on spinal fracture risk in a national cohort of patients with AS.

Enrollment: 9,858 patients

Sex: All

Ages: 30 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 30-60 years
• registered diagnosis of ankylosing spondylitis

Exclusion criteria

• age <30 or >60 years

Trial design

9,858 participants in 1 patient group

AS patients

Description:

Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures

Treatment:

Drug: bDMARD treatment